All In Biotech

Drug Trial Radar · NCT05743036

ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

A Phase 1/2, Open-Label, Multi-Center Study of ZN-c3 Administered in Combination With Encorafenib and Cetuximab in Adults With Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Aug 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

44

Actual

Start

Feb 27, 2023

Primary completion

Jul 16, 2024

Study completion Jul 9, 2025

Sponsor

Sponsor type
Industry
Collaborators
Pfizer
First posted
Feb 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult participants with metastatic BRAF V600E mutant colorectal cancer previously treated with one or two treatment regimens.

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • ZN-c3Drug

    ZN-c3 tablet by mouth, in combination with encorafenib

  • EncorafenibDrug

    Encorafenib capsule by mouth, in combination with ZN-c3

  • CetuximabDrug

    Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation Phase - Incidence of Dose Limiting Toxicities (DLTs)Time frame: From Lead-in Day -1 to Cycle 1 Day 28
  2. Dose Expansion Phase - Objective response rate (ORR)Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months

Locations

27 sites in 7 countries. Site status is shown where the registry gives one.

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • Alliance for Multispecialty Research, LLC

    Merriam, Kansas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • The Queen Elizabeth Hospital

    Woodville South, South Australia, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Hämatologie- Onkologie im Zentrum MVZ GmbH

    Augsburg, Bavaria, Germany

  • Klinikum der Universität München Großhadern

    Munich, Bavaria, Germany

  • Muenchen Klinik Neuperlach, Klinik fuer Haematologie und Onkologie

    Munich, Bavaria, Germany

  • Institut für Klinisch Onkologische Forschung

    Frankfurt am Main, Hesse, Germany

  • DRK Kliniken Berlin - Köpenick

    Berlin, State of Berlin, Germany

  • Clinexpert Kft. Bugat Pal Korhaz

    Gyöngyös, Hungary

  • Semmelweis University-Department of Internal Medicine and Oncology

    Budapest, Budapest, Hungary

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale

    Naples, Campania, Italy

  • IRCCS Casa Sollievo della Sofferenza

    San Giovanni Rotondo, Foggia, Italy

  • Istituto Europeo di Oncologia

    Milan, Milano, Italy

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Milano, Italy

  • AOUI Verona

    Verona, Veneto, Italy

  • Szpital Uniwersytecki w Krakowie

    Krakow, Lesser Poland Voivodeship, Poland

  • Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie

    Krakow, Lesser Poland Voivodeship, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie

    Warsaw, Masovian Voivodeship, Poland

  • Opolskie Centrum Onkologii w Opolu im. prof. Tadeusza Koszarowskiego

    Opole, Opole Voivodeship, Poland

  • Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona, Spain

  • Parc de Salut Mar - Hospital del Mar

    Barcelona, Catalonia, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, Cordoba, Spain

  • Hospital Universitario La Paz

    Madrid, Madrid, Spain

  • Hospital Universitario Puerta de Hierro Majadahonda

    Madrid, Madrid, Spain

  • Fundación Instituto Valenciano de Oncología

    Valencia, Valenciana, Comunitat, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.